Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014-12-01
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
ABSTRACT
PURPOSE
We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC).
PATIENTS AND METHODS
Patients had stage III to IV carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Radiation therapy schedules were 70 Gy in 35 fractions over 7 weeks (SFX) or 72 Gy in 42 fractions over 6 weeks (AFX-C). Cisplatin doses were 100 mg/m(2) once every 3 weeks for two (AFX-C) or three (SFX) cycles. Toxicities were scored by using National Cancer Institute Common Toxicity Criteria 2.0 and the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer criteria. Overall survival (OS) and progression-free survival (PFS) rates were estimated by using the Kaplan-Meier method and were compared by using the one-sided log-rank test. Locoregional failure (LRF) and distant metastasis (DM) rates were estimated by using the cumulative incidence method and Gray's test.
RESULTS
In all, 721 of 743 patients were analyzable (361, SFX; 360, AFX-C). At a median follow-up of 7.9 years (range, 0.3 to 10.1 years) for 355 surviving patients, no differences were observed in OS (hazard ratio [HR], 0.96; 95% CI, 0.79 to 1.18; P = .37; 8-year survival, 48% v 48%), PFS (HR, 1.02; 95% CI, 0.84 to 1.24; P = .52; 8-year estimate, 42% v 41%), LRF (HR, 1.08; 95% CI, 0.84 to 1.38; P = .78; 8-year estimate, 37% v 39%), or DM (HR, 0.83; 95% CI, 0.56 to 1.24; P = .16; 8-year estimate, 15% v 13%). For oropharyngeal cancer, p16-positive patients had better OS than p16-negative patients (HR, 0.30; 95% CI, 0.21 to 0.42; P < .001; 8-year survival, 70.9% v 30.2%). There were no statistically significant differences in the grade 3 to 5 acute or late toxicities between the two arms and p-16 status.
CONCLUSION
When combined with cisplatin, AFX-C neither improved outcome nor increased late toxicity in patients with LA-HNC. Long-term high survival rates in p16-positive patients with oropharyngeal cancer support the ongoing efforts to explore deintensification.
Related Questions
At what point would you consider the treatment break to be too long for curative treatment?
New answer by Radiation Oncologist at University of Michigan (October 2, 2018)
Continuing therapy after a break depends on several factors. The timing of the break is important: Little repopulation occurs in the first 3-4 weeks of standard RT, and then i...
Consider 6 fractions weekly chemoRT? Add cetuximab to chemoRT? Proton boost? Induction chemo prior to chemoRT? Interstitial H&N brachytherapy boos...
New comment by Radiation Oncologist at University of Florida ( January 22, 2021)
It would probably give you an extra bump. The RTOG trial used the MD Anderson concomitant boost which was inferior to hyper fractionation in 90-03.
How do you decide on other chemo regimen? (Dosing, frequency, carboplatin based, non-platinum based etc.)
Would you use Cetuximab?
Altered fractiona...
New answer by Radiation Oncologist at University of Florida (August 25, 2020)
Hyperfractionation and carboplatin
Should the dose still be given after completion of RT?
New answer by Medical Oncologist at Vanderbilt (September 27, 2022)
Cisplatin added radiation for the purpose of radiosensitization should only be administered during radiation and studies indicate no benefit but added toxicity with a 3rd cycl...
If using cetuximab, would you recommend accelerated fractionation?
New answer by Radiation Oncologist at University of Florida (June 27, 2023)
Altered fractionation, preferably hyper fractionation, and a taxane. If hyper fractionation is not an option, 6-week SIB.